Fostering collaborative research, tech transfer and spin off projects, thus addressing the needs of European Biotech enterprises is the service that EuroBiO is willing to propose to the life sciences community. While the seed and VC investments in the sector will most certainly remain stable in the coming months, the amount of acquisitions of biotech companies by the pharmaceutical industry will on the contrary most probably increase. In the meantime, research grants and subsidies obtained by biotech companies in the frame of collaborative programs will also keep on growing.

In such a context, taking part to EuroBiO - the event positioning itself as the leading moment for collaborative research and tech transfer - is more than ever useful. EuroBiO 2009 is bringing a new ambition to the event, one that is tailored to the needs and challenges of both companies and academia.

Our commitment to the Bioindustry is to be a cutting-edge platform for partnerships creating Europe’s first marketplace for academia-industry interaction with the aim of fostering technology transfer and collaborative research projects. Moreover, EuroBiO is a hub for innovative emerging companies that are making astounding advances in biotechnology therapies, vaccines, diagnostics, etc.

EuroBiO 2009 therefore represents a great opportunity for Meeting key partners, Sharing experience with leaders and experts in industry and Expanding your business through a successful partnering…